Skip to main content

Table 2 Variation in the mean weight, mean BMI, mean tPSA and the proportion of participants with ECOG scores > 1 for the GnRHa subgroup, BTO subgroup and the control group

From: Quantifying the changes in body mass index and performance status during androgen deprivation therapy for advanced prostate cancer in southeast Nigeria

Variable

Timing

GnRHa (p value)

BTO (p value)

Control (p value)

Mean weight (kg)

Inception

65.7 ± 9.6

67.0 ± 10.7

68.6 ± 11.2

 

2nd month

65.9 ± 9.3 (p 0.41)

67.8 ± 10.5 (p < 0.001)

68.6 ± 11.2 (p 0.52)

 

4th month

67.0 ± 9.8 (p 0.007)

69.0 ± 10.5 (p < 0.001)

68.7 ± 11.0 (p 0.48)

 

6th month

67.8 ± 10.0 (p 0.001)

70.2 ± 10.7 (p < 0.001)

68.7 ± 11.0 (p 0.22)

Mean BMI (kg/m2)

Inception

25.2 ± 5.2

25.1 ± 3.4

25.5 ± 4.6

 

2nd month

25.2 ± 4.9 (p 0.79)

25.4 ± 3.4 (p < 0.001)

25.5 ± 4.6 (p 0.46)

 

4th month

25.6 ± 5.1 (p 0.004)

25.9 ± 3.4 (p < 0.001)

25.5 ± 4.6 (p 0.41)

 

6th month

26.0 ± 5.2 (p < 0.001)

26.4 ± 3.5 (p < 0.001)

25.5 ± 4.6 (p 0.24)

Proportion with ECOG score > 1 (%)

Inception

85.7%

83.5%

 
 

2nd month

72.0% (p 0.001)

46.2% (p < 0.001)

 
 

4th month

33.3% (p < 0.001)

34.8% (p < 0.001)

 
 

6th month

25.0% (p < 0.001)

19.0% (p < 0.001)

 

Mean tPSA (ng/ml)

Inception

38.2 ± 23.3

47.2 ± 33.0

 
 

3rd month

9.2 ± 6.9 (p < 0.001)

14.4 ± 19.2 (p < 0.001)

 
 

6th month

5.0 ± 3.4 (p 0.001)

8.5 ± 16.2 (p < 0.001)

 
  1. GnRHa gonadotropin-releasing hormone analogue; BTO bilateral total orchidectomy; BMI body mass index; ECOG Eastern Cooperative Oncology Group; tPSA serum total prostate-specific antigen